97570-29-1

Usage

Uses

Used in Pharmaceutical Industry:
2-Amino-6-hydroxy-5-(2-propenyl)-4(1H)-pyrimidinone is used as an intermediate in the synthesis of pharmaceuticals for its potential biological and medicinal properties.
Used in Antioxidant and Anti-inflammatory Applications:
2-Amino-6-hydroxy-5-(2-propenyl)-4(1H)-pyrimidinone is used as an antioxidant and anti-inflammatory agent due to its potential biological effects.
Used in Cancer Treatment:
2-Amino-6-hydroxy-5-(2-propenyl)-4(1H)-pyrimidinone is used as a potential therapeutic agent in the treatment of cancer.
Used in Neurodegenerative Disease Treatment:
2-Amino-6-hydroxy-5-(2-propenyl)-4(1H)-pyrimidinone is used as a potential therapeutic agent in the treatment of neurodegenerative diseases.

InChI:InChI=1/C7H9N3O2/c1-2-3-4-5(11)9-7(8)10-6(4)12/h2H,1,3H2,(H4,8,9,10,11,12)

Upstream product

• 2049-80-1 (2-propenyl)propanedioic acid diethyl ester 
• 50-01-1 guanidine hydrochloride 

Downstream Products

• 99044-54-9 2-amino-7-benzyl-4-chloropyrrolo<2,3-d>pyrimidine 
• 99044-52-7 N⁴-Benzyl-6-chloro-5-(2,2-diethoxy-ethyl)-pyrimidine-2,4-diamine 
• 96080-37-4 2-amino-7-benzylpyrrolo<2,3-d>pyrimidin-4-one 
• 97570-30-4 5-allyl-4,6-dichloro-2-aminopyrimidine 
• 1380343-13-4 2-amino-4-chloro-7-(4-methoxy)benzyl-pyrrolidino[2,3-d]pyrimidine 
• 1380343-14-5 2-n-propylamino-4-chloro-7-(4-methoxy)benzyl-pyrrolidmo[2,3-d]pyrimidine 
• 97643-11-3 (+/-)-2-amino-3,4-dihydro-7-<(1α,2α,3α,4α)-2,3-dihydroxy-4-(hydroxymethyl)-1-cyclopentyl>-7H-pyrrolo<2,3-d>pyrimidin-4-one 
• 97570-35-9 (+/-)-2-amino-3,4-dihydro-7-<(1α,2α,3β,4α)-2,3-dihydroxy-4-(hydroxymethyl)-1-cyclopentyl>-7H-pyrrolo<2,3-d>pyrimidin-4-one 

Relevant academic research and scientific papers

Ultrasound-assisted rapid synthesis of 2-aminopyrimidine and barbituric acid derivatives

Novel, inexpensive, and relatively expeditious procedure to achieve the synthesis of different 2-aminopyrimidine and barbituric acid derivatives is presented here, starting from readily available compounds such as guanidine hydrochloride, urea, 1,3-dialkylurea, or thiourea. Under ultrasonic irradiation, base-driven (Na2CO3, NaOH, or NaOC2H5) heterocyclization reactions of the aforementioned substrates with diethyl malonate, diethyl-2-alkyl malonate, pentane-2,4-dione, or ethyl-3-oxobutanoate yielded corresponding products. Significant advantages of this sonochemical synthetic protocol with regard to the conventional thermal methods include easy reaction setup and work-up steps, reasonably mild conditions, shorter reaction times (～30 min) and comparably high product yields. The characterization of the synthesized compounds was based on melting points, FT-IR, GC-MS, 1H-NMR techniques, and the obtained data were also checked from the previously published studies.

5-substituted 2-amino-4,6-dihydroxypyrimidines and 2-amino-4, 6-dichloropyrimidines: Synthesis and inhibitory effects on immune-activated nitric oxide production

A series of 5-substituted 2-amino-4,6-dihydroxypyrimidines were prepared by a modified condensation of the corresponding monosubstituted malonic acid diesters with guanidine in an excess of sodium ethoxide. The optimized procedure using Vilsmeier-Haack-Arnold reagent, followed by immediate deprotection of the (dimethylamino)methylene protecting groups, has been developed to convert the 2-amino-4,6-dihydroxypyrimidine analogs to novel 5-substituted 2-amino-4,6-dichloropyrimidines in high yields. Pilot screening for biological properties of the prepared compounds was done in mouse peritoneal cells using the in vitro nitric oxide (NO) assay. Irrespective of the substituent at the 5 position, 2-amino- 4,6-dichloropyrimidines inhibited immune-activated NO production. The most effective was 5-fluoro-2-amino-4,6- dichloropyrimidine with an IC50 of 2 μM (higher activity than the most potent reference compound) while the IC50s of other derivatives were within the range of 9-36 l M. The 2-amino-4,6-dihydroxypyrimidine counterparts were devoid of any NO-inhibitory activity. The compounds had no suppressive effects on the viability of cells. The Mechanism of action remains to be elucidated.

5-Substituted 2-amino-4, 6-dihydroxypyrimidines and 2-amino-4, 6-dichloropyrimidines: Synthesis and inhibitory effects on immune-activated nitric oxide production

A series of 5-substituted 2-amino-4, 6-dihydr-oxypyrimidines were prepared by a modified condensation of the corresponding monosubstituted malonic acid diesters with guanidine in an excess of sodium ethoxide. The optimized procedure using Vilsmeier-Haack-Arnold reagent, followed by immediate deprotection of the (dimethylamino)methylene protecting groups, has been developed to convert the 2-amino-4, 6-dihydroxypyrimi-dine analogs to novel 5-substituted 2-amino-4, 6-dichloro-pyrimidines in high yields. Pilot screening for biological properties of the prepared compounds was done in mouse peritoneal cells using the in vitro nitric oxide (NO) assay. Irrespective of the substituent at the 5 position, 2-amino-4, 6-dichloropyrimidines inhibited immune-activated NO production. The most effective was 5-fluoro-2-amino-4, 6-dichloropyrimidine with an IC50 of 2 lM (higher activity than the most potent reference compound) while the IC50s of other derivatives were within the range of 9-36 μM. The 2-amino-4, 6-dihydroxypyrimidine counterparts were devoid of any NO-inhibitory activity. The compounds had no suppressive effects on the viability of cells. The Mechanism of action remains to be elucidated.

PYRIMIDINE COMPOUNDS INHIBITING THE FORMATION OF NITRIC OXIDE AND PROSTAGLANDIN E2, METHOD OF PRODUCTION THEREOF AND USE THEREOF

The invention provides pyrimidine compounds of general formula (I), which reduce simultaneously the production of nitric oxide (NO) and prostaglandin E2 (PGE2). They have no negative effect on the viability of cells in concentrations decreasing the production of these factors by up to 50%; they are not cytotoxic. Furthermore, a method of preparation of the pyrimidine compounds of general formula (I), carrying 2-formamido group, a pharmaceutical composition comprising the substituted pyrimidine compounds according to the invention, and the use of these compounds for the treatment of inflammatory and cancer diseases are provided.˙

NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES

The present invention includes compositions that are useful in the treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention, The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention.

CERTAIN SUBSTITUTED PYRIMIDINES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE

Provided are certain Hsp90 inhibitors, i.e., compounds of Formula I and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods for their use and preparation.

METHODS OF TREATING COGNITIVE IMPAIRMENT AND DEMENTIA

This invention relates to methods for treating, managing and preventing cognitive impairment associated with various diseases and disorders, age-associated memory impairment, and dementia.

(±)-2-Amino-3,4-dihydro-7-[2,3-dihydroxy-4-(hydroxymethyl)-1-cyclopentyl ]-7H-pyrrolo[2,3-d]pyrimidin-4-ones: New carbocyclic analogues of 7-deazaguanosine with antiviral activity

5-Allyl-2-amino-4,6-dihydroxypyrimidine was chlorinated and ozonized to yield (2-amino-4,6-dichloro-pyrimidin-5-yl)acetaldehyde (5). Acetalization of 5 with ethanol afforded a new pyrimidine intermediate which can lead to 2-amino-3,4-dihydro-7-alkyl-7H-pyrrolo[2,3-d]pyrimidin-4-ones and therefore to carbocyclic analogues of 7-deazaguanosine. The 7-substituent was a cyclopentyl analogue of the arabinofuranosyl moiety in 10a, lyxofuranosyl moiety in 10b, and ribofuranosyl moiety in 10c. Compounds 10a and 10b exhibited selective inhibitory activities against the multiplication of HSV1 and HSV2 in cell culture. Repeated administration of compound 10a at 10 mg/kg ip to mice infected with HSV2 increased the number of survivors and lengthened significantly the mean survival time.